LRRK2, GBA and Other Genetic Biomarkers in Eastern European (Ashkenazi) Jews With and Without Parkinson's Disease
NCT ID: NCT04668898
Last Updated: 2025-04-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
203 participants
OBSERVATIONAL
2019-04-01
2025-04-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Longitudinal Study in Parkinson's Disease (PD) Patients
NCT01730599
Biomarker Analysis for GBA Associated Parkinson's Disease
NCT03811496
Characteristics of Parkinson s Disease Associated With the LRRK-2 Gene Mutation
NCT00467090
LRRK2 Activity and Markers of Parkinson's Disease in G2385R Carriers
NCT04349865
Prodromal Parkinsonian Features in GBA1 Mutation Carriers
NCT05253560
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
LRRK2 Parkinson Disease
Individuals with LRRK2-related Parkinson Disease
No interventions assigned to this group
GBA Parkinson Disease
Individuals with GBA-related Parkinson Disease
No interventions assigned to this group
Idiopathic Parkinson Disease
Individuals with Idiopathic (without any known genetic cause) Parkinson Disease
No interventions assigned to this group
LRRK2 non-manifesting carriers
Individuals without Parkinson Disease who have a LRRK2 mutation
No interventions assigned to this group
GBA non-manifesting carriers
Individuals without Parkinson Disease who have a GBA mutation
No interventions assigned to this group
Healthy control
Individuals without a personal or family history (1st or 2nd degree) of a neurodegenerative disease
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants must be local to the New York City area and willing to come to Mount Sinai Downtown for annual 2 hour study visits which include obtaining personal medical and family history information, blood, urine and spinal fluid samples, neurological exam and neuropsychiatric testing. Spinal fluid collection is encouraged but optional.
Exclusion Criteria
30 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Massachusetts General Hospital
OTHER
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Icahn School of Medicine at Mount Sinai
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Rachel Saunders-Pullman
Professor, Neurology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Rachel Saunders-Pullman, MD, MPH
Role: PRINCIPAL_INVESTIGATOR
Icahn School of Medicine at Mount Sinai
Laurie Ozelius, PhD
Role: PRINCIPAL_INVESTIGATOR
Massachusetts General Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mount Sinai-- Downtown Union Square
New York, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Informed Consent Form
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GCO 17-1846
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.